Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From C.R. Bard

Will Beovu Be A Slow-Burning Blockbuster?

Expanded indications will be key for Novartis's Beovu and a successful diabetic macular edema trial has provided a fillip, a week after the wet AMD-approved drug posted a 44% slump in sales.

Ophthalmic Clinical Trials

Samsung Bioepis Nudges Closer To Ranibizumab Approvals With New Data

Samsung Bioepis has been tight-lipped on the potential to win approval for its SB11 biosimilar ranibizumab product this year, though new similarity data is a further positive omen for the Korea-based biosimilar player.

Biosimilars Clinical Trials

Organon Is Ready To Launch And Makes The Case To Investors

Merck & Co. plans to spin off Organon in June as a diversified health care company focused on women's health, biosimilars and established products.

Business Strategies Biosimilars

The Drugs That Could Face US Generic/Biosimilar Competition In 2021

Other expected generics include Viatris' Perforomist (formoterol fumarate), Pfizer's Sutent (sunitinib), Sanofi's Jevtana (cabazitaxel) and possibly Boehringer Ingelheim's Pradaxa.

Biosimilars Generic Drugs
See All

Company Information

  • Industry
  • Medical Devices
  • Other Names / Subsidiaries
    • Davol, Inc.
    • Embo Medical Limited
    • Liberator Medical, Inc.
    • Lutonix, Inc.
    • Medafor, Inc.
    • Medicon, Inc.
    • Neomend, Inc.
    • Rochester Medical, Inc.
    • Vascular Pathways, Inc.
    • FlowCardia, Inc.
    • Bridger Biomed, Inc.
UsernamePublicRestriction

Register